NCT01964183View on ClinicalTrials.gov

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Pharmacokinetics of Mirabegron and TolterodineHealthy
Interventions
DRUG

tolterodine

Oral

DRUG

mirabegron

Oral

Trial Locations (1)

Unknown

Kanto

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT01964183 - Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine | Biotech Hunter | Biotech Hunter